Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 24 June 2013 | By Alexander Gaffney, RAC,
Since 2008, the US Food and Drug Administration (FDA) has only approved six prescription drug products for sale on an over-the-counter (OTC) basis without a prescription - a process known as an OTC "switch." Soon, a seventh drug may be joining their ranks.
In an announcement in the Federal Register on 24 June 2013, FDA said it would soon hold a meeting of its Nonprescription Drugs Advisory Committee (NDAC) to discuss a supplemental new drug application (sNDA) for Nasacort AQ (triamcinolone acetonide nasal spray) filed by French pharmaceutical manufacturer Sanofi-Aventis.
If approved, Nasacort AQ would be the third allergy product switched to OTC status since 1 January 2007. In 2007, FDA approved four variants of the antihistamine Zyrtec, and in 2011 approved three variants of the antihistamine Allegra.
As with the other allergy medications, Sanofi's Nasacort AQ would, if approved, be indicated for the temporary relief of symptoms associated with hay fever or other respiratory allergies, including nasal congestion, runny nose, sneezing and itchy nose. In addition, the drug is being supported with data regarding its use in both adults and children.
NDAC will be charged with issuing a recommendation to FDA on whether Nasacort AQ is safe for use in a broad range of unsupervised consumers who must self-select for treatment. FDA noted the data to be discussed will include adverse event data and postmarket experience data regarding systemic and local effects.
FDA's switch of Nasacort AQ would also mark its second switch since announcing a new "partial switch" paradigm in 2012. In January 2013 the agency granted partial OTC status to Oxytrol, a bladder control drug that was given OTC status for women. In men, regulators said they feared use of the drug could potentially mask prostate cancer, and kept the drug under prescription-only status.
The meeting will be held on 31 July 2013 in Silver Spring, MD.
Federal Register Notice
Regulatory Focus newsletters
All the biggest regulatory news and happenings.